PATENT CLAIM ANALYSIS

Application Number: 16061974
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Claim (Index 16):
The composition of  claim 4 , where the composition comprises about 200 mg of X4P-001, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 94.0
- Lexical Diversity: 1.29787
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12937630', '15553570', '15805390', '14905776', '12671287']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.734283428330147
- 35 USC 102 Novelty (BERT): 0.5110356894612577
- Combined Prediction Score: 0.7119586544432581
- Mean Citation Score: 186.025422
- Max Citation Score: 194.66278
- Similarity Product: 120.82233790731428

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test